ATRX and cancer: PARP inhibitors, already approved for the treatment of homologous recombination-deficient cancers, may exhibit enhanced therapeutic efficacy in ALT-positive tumors, especially those harboring ATRX/DAXX loss of function, due to increased reliance on recombination-mediated telomere maintenance [63,64,65,66,67,68,69,70].